Antalpha Increases Investment in Aurelion with US$2 Million Share Subscription

SINGAPORE, Oct 23 (Bernama-GLOBE NEWSWIRE) -- Antalpha Platform Holding Company (NASDAQ: ANTA) ("Antalpha"), a leading institutional digital asset financing platform, today announced that its wholly owned subsidiary, Antalpha Capital (HK) Limited, has entered into a share subscription agreement with Aurelion Inc. (NASDAQ: AURE) ("Aurelion" or the "Company"). Under the agreement, Antalpha, through Antalpha Capital (HK) Limited, will subscribe for 952,381 newly issued Class B ordinary shares of Aurelion at a price of US$2.10 per share, for aggregate gross proceeds to Aurelion of approximately US$2 million (the "Subscription"). The Subscription is expected to close as soon as practicable, subject to customary closing conditions and a long-stop date of December 21, 2026.

Antalpha currently holds 31.7% of the ordinary shares of Aurelion's issued and outstanding shares, based on Aurelion's outstanding shares/pre-funded warrants/primary warrants, representing approximately 77.5% of Aurelion's total voting power. Upon completion of the subscription, Antalpha is expected to hold approximately 33.4% of Aurelion's issued and outstanding shares, based on Aurelion’s outstanding shares/pre-funded warrants/primary warrants representing approximately 78.8% of Aurelion's total voting rights.

“Increasing our investment in Aurelion reflects our continued confidence in its strategy and the long-term potential of tokenized gold,” said Paul Liang, Chief Financial Officer of Antalpha. “Aurelion’s focus on digital gold infrastructure complements our expertise in financing and risk management. Through this additional commitment, we are supporting the development of practical institutional applications for tokenized gold, with disciplined execution and long-term shareholder value as our priorities.”

“Antalpha’s continued support as our controlling shareholder reinforces its commitment to Aurelion’s next phase of development,” said Frank Zheng, Chief Executive Officer of Aurelion. “Upon closing, this investment would provide additional financial flexibility as we advance our digital gold business. Our focus is on building the technology and risk-management capabilities that institutions need to use tokenized gold with confidence.”

About Antalpha

Antalpha is a leading fintech company specializing in providing financing, technology, and risk management solutions to the Web3 industry. Antalpha offers Bitcoin supply chain and margin loans through the Antalpha Prime technology platform, which allows customers to originate and manage their digital assets loans, as well as monitor collateral positions with near real-time data. Building on this foundation, Antalpha is also exploring AI-powered tools to help users navigate the digital asset space more effectively.

About Aurelion

Aurelion is a publicly listed company building a digital gold risk and technology infrastructure around XAU₮, on-chain gold backed by physical LBMA bars. Combining the characteristics of physical gold with the efficiency of blockchain technology, XAU₮ serves as the foundation of Aurelion's digital gold treasury strategy. The Company is committed to the prudent management and efficient utilization of its proprietary digital gold holdings, while providing risk management and technical support for selected tokenized gold initiatives. Through its technology-driven approach, Aurelion seeks to contribute to the responsible development and broader adoption of digital gold and tokenized asset solutions.

Safe Harbor Statement

This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to," and similar statements. Statements that are not historical facts, including statements about Antalpha's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in Antalpha's filings with the SEC. All information provided in this press release is as of the date of this press release, and Antalpha does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Contacts

Investor Contact: ir@antalpha.com

SOURCE: Antalpha Platform Holding Company

DISCLAIMER: BERNAMA MREM are not accountable for any causes of website defacement, misuse, or illegal activities connected to cryptocurrency, blockchain, tokenisation, or bitcoin. This material should not be considered as guidance or an opinion, as it does not constitute financial or investment advice. Use this information at your own risk; we are not liable for any losses or damages caused by the republication of this article.

Genon Clears Nike Footwear Production Validation, Wins New AI Automation Contracts in Indonesia

 

^{Genon’s AI solution analyzes vessel documents and automatically generates reports. (Image: Genon)}


JAKARTA, Indonesia, Oct 21 (Bernama-BUSINESS WIRE) -- Genon, a South Korean generative AI solutions startup, announced on Wednesday, Oct. 21, that its Indonesian AI manufacturing automation business passed mass-production validation and won follow-on contracts, accelerating its overseas expansion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020059682/en/ 

Last year, Genon developed Vision AI inspection technology for Nike that automatically identifies defective outsoles. The AI analyzes surfaces captured with industrial high-resolution cameras and dedicated lighting, locating defects and grading products pass or fail against product-specific standards. This year’s mass-production validation achieved 99.7% and 99.2% defect detection rates on two styles, respectively, clearing Nike Footwear’s final validation.

Conducted for production-line deployment rather than mere performance evaluation, the validation paves the way for commercialization. Genon is preparing the mass-production model: development starts before year-end, with deployment beginning in 2027, and phased expansion to more products and lines.

Building on this, Genon won a Vision AI project this year to detect micro-defects in stitched and bonded areas of shoe uppers, using ultra-high-resolution cameras and multi-angle lighting to capture their complex structures. Inspection will later extend to midsoles and finished products, supporting quality-control automation across footwear manufacturing.

Genon secured a Physical AI contract to automate production by pairing collaborative robots with vision cameras for repetitive outsole-pressing tasks. It will combine existing robot control with AI-based motion generation, enabling robots to recognize objects and move accordingly, and learn skilled motions from operators’ teleoperation demonstrations—all to achieve 24-hour continuous operation and greater process efficiency.

Through these contracts, PT Genon Global Indonesia, Genon’s subsidiary established this year led by President and Managing Director Tae Ryong Kim, targets first-year profitability. Genon will continue pursuing Vision AI and Physical AI opportunities to strengthen its base in Indonesia.

Beyond footwear, Genon is exploring shipbuilding and offshore industries, leveraging its manufacturing automation business in Indonesia. A prime example is an AI solution under development for global offshore engineering firm IKM Group to analyze vessel-related documents and automatically generate work-plan reports. Building on these solutions, Genon plans to gradually expand its opportunities in the global market.

Seok Tae Ko, CEO of Genon, said, “In AI manufacturing automation, competitiveness depends not only on technical accuracy but on understanding real production environments and on-site deployment capability.” He added, “We will deepen collaboration with local customers and advance our execution capabilities, from development through commercialization, to build a sustainable foundation for overseas growth.”

About Genon Inc.

Generative AI On – GenOn. Genon is a leading AI technology company specializing in Generative AI-driven B2B solutions. The company leverages extensive IT experience, industry insights, and proven technical expertise to deliver AI innovations that drive real-world business impact. Additional information is available at www.genon.ai/en

View source version on businesswire.com:
https://www.businesswire.com/news/home/20261020059682/en/

Contact

Somiy Jeon
pr@genon.ai

Source : Genon Inc.

Abaxx Exchange Named Newcomer of the Year at Energy Risk Asia Awards

Second Energy Risk award of 2026 recognizes Abaxx’s work to meet global demand for modern commodity benchmarks


TORONTO and SINGAPORE, Oct 21 (Bernama-GLOBE NEWSWIRE) -- Abaxx Technologies Inc. (TSX:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), today announced that Risk.net has named Abaxx Exchange “Newcomer of the Year” at the 2026 Energy Risk Asia Awards.

The Energy Risk Asia Awards recognize innovation and expertise in commodity trading and risk management across the Asia-Pacific region. This award brings further regional recognition to Abaxx Exchange, following its Newcomer of the Year win at the Energy Risk Awards in May. This category recognizes emerging companies, or established firms entering new markets, that have demonstrated growth, market relevance, and contribution within their first three years of operation.

Since trading commenced in June 2024, Abaxx Exchange has introduced 18 commodity futures contracts, including the only physically deliverable LNG futures traded globally and the only U.S. dollar-denominated, physically deliverable nickel sulphate and lithium carbonate futures outside China. In precious metals, Abaxx offers U.S. dollar-denominated kilobar gold futures and 1,000-troy-ounce, four-nines silver futures, both are the only of their kind deliverable into Singapore. Its Gold Singapore (GKS) contract was named Best Innovation by an Exchange or Clearing House at the 2026 FOW Asia Pacific Awards last month.

“It’s an honor to receive our second Energy Risk award this year, recognizing our role in connecting global commodity markets,” said Russell Robertson, Chief Business Development Officer at Abaxx Exchange. “Energy systems and trade flows are changing and market participants need new tools to better manage risk. Abaxx is introducing new commodity futures benchmarks to meet that need, and we are grateful to our growing trading and clearing community for their partnership as we support Singapore’s role as a vital trading center connecting the global economy.”

About Abaxx Technologies

Abaxx Technologies Inc. (TSX: ABXX | OTCQX: ABXXF) is building Smarter Markets: markets empowered by better tools, better benchmarks, and better technology to drive market-based solutions to the biggest challenges we face as a society, including the energy transformation and the transition to an AI-augmented economy.

In addition to developing and deploying financial technologies that make communication, trade, and transactions easier and more secure, Abaxx is the majority shareholder of Abaxx Singapore, the owner of Abaxx Exchange and Abaxx Clearing, parent company of wholly owned subsidiaries Abaxx Spot and Adaptive Infrastructure, and founder of Abaxx Labs and the SmarterMarkets™ podcast.

For more information, visit investors.abaxx.tech, abaxx.exchange, abaxxspot.com and smartermarkets.media

For more information about this press release, please contact:
Steve Fray, CFO
Tel: +1 647-490-1590

Media Inquiries
Tara Hayes
Email: tara@abaxx.tech

Investor Inquiries
Tel: +1 246 271 0082
E-mail: ir@abaxx.tech

Cautionary Statement Regarding Forward-Looking Information

This press release includes certain “forward-looking statements” and “forward-looking information” (collectively, “forward-looking statements”) within the meaning of applicable Canadian and United States securities laws. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “believe”, “anticipate”, “estimate”, “project”, “intend”, “expect”, “may”, “will”, “plan”, “should”, “would”, “could”, “target”, “propose”, “goal”, “objective”, “ongoing”, “potential”, “likely” or the negative thereof or similar expressions.

In particular, this press release contains forward-looking statements including, without limitation, Abaxx’s objectives and future plans and the introduction of the next generation of commodity futures benchmarks to meet the needs of market participants. Forward-looking statements are based on the reasonable assumptions, estimates, analyses and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Such factors impacting forward-looking information include, among others: risks relating to the global economic climate; the risk that trading volume, average daily volume, and open interest on Abaxx Exchange may not continue to grow, or may decline, if the liquidity-related credits provided under Abaxx’s market maker and liquidity provider programs are reduced, discontinued, or otherwise changed, or if market participants who currently trade on Abaxx Exchange in connection with such programs do not continue to trade, or do not increase their trading activity, independently of such programs; failure or delays related to the onboarding of clearing members; dilution; Abaxx’s limited operating history; future capital needs and uncertainty of additional financing; the competitive nature of the industry; currency exchange risks; the need for Abaxx to manage its planned growth and expansion; the effects of product development and need for continued technology change; protection of intellectual property and proprietary rights; the effect of government regulation and compliance on Abaxx and the industry; acquiring and maintaining regulatory approvals for Abaxx’s products and operations; the ability to list Abaxx’s securities on stock exchanges in a timely fashion or at all; the failure of energy, commodity markets and collateral use cases to develop according to the expectations of Abaxx; risks related to operations in foreign jurisdictions; network security risks; the ability of Abaxx to maintain properly working systems; reliance on key personnel; contractual risk; third-party risk; clearinghouse risk; malicious actor risks; third-party software license risk; system failure risk; risk of technological change; global economic and financial market deterioration impeding access to capital or increasing the cost of capital; volatile securities markets impacting security pricing unrelated to operating performance; changes in global weather patterns; changes in the price of commodities, capital market conditions, restrictions on labor and international travel and supply chains, and the risk factors identified in the Company’s most recent management’s discussion and analysis filed on SEDAR+. In addition, particular assumptions which could impact future results of the business of Abaxx include, but are not limited to, Abaxx’s assumption that: trading volume and liquidity on Abaxx Exchange will continue to develop over time, independently of its market maker and liquidity provider programs; additional clearing members will complete onboarding and begin clearing activities according to Abaxx’s expectations; Abaxx will be able to execute its business plan and growth strategy; Abaxx will retain or successfully replace its key personnel; Abaxx will protect its intellectual property rights; energy and commodity markets will continue to develop according to Abaxx’s expectations; collateral use cases for Abaxx’s products will develop in line with Abaxx’s expectations, the demand for centrally cleared, physically deliverable futures and derivatives will grow as anticipated; regulatory approvals required for Abaxx’s products and operations will remain in good standing or will be obtained as required; applicable laws and regulations will not change in a way that adversely affects Abaxx’s business, and that its technology, systems and infrastructure will operate as intended without significant failure, security breach or disruption; third-party service providers, clearing and settlement partners and other service providers will continue to perform their obligations and act according to Abaxx’s expectations; general economic and capital market conditions, commodity prices, currency exchange rates and the supply chain environment will not deteriorate in a way that materially affects Abaxx or its participants, and that Abaxx’s competitive environment will not change materially. Abaxx has also assumed that no significant events occur outside of Abaxx’s normal course of business.

Abaxx cautions that the foregoing list of material factors and assumptions is not exhaustive. In addition, although Abaxx has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, or intended. When relying on forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. There can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking statements and information contained in this press release represent the expectations of Abaxx as of the date of this press release and, accordingly, are subject to change after such date. Abaxx undertakes no obligation to update or revise any forward-looking statements and information, whether as a result of new information, future events or otherwise, except as required by law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements and information. Neither the Toronto Stock Exchange nor any other securities exchange or regulatory authority accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Abaxx Technologies Inc.

​Digital Science and Sunmedia partner to bring research impact reporting to Japan's medical affairs teams

^{Digital Science Logo}


Tokyo, Japan and London, United Kingdom, UK, Oct.20,2026 / Agility PR - AsiaNet / --

New reports help medical affairs teams connect published research to real-world outcomes, including clinical guidelines

Digital Science , a leading technology company serving stakeholders across the research ecosystem, today announced a partnership with Sunmedia , a Tokyo-based scholarly information company, to help medical affairs teams across Japan understand the impact of their research.

Under the partnership, Sunmedia will develop customized, narrative-driven reports using Digital Science’s Dimensions and Altmetric data, helping medical affairs teams show how their published research and independent medical education (IME) activity translate into real-world outcomes, such as clinical guidelines.

The reports help medical affairs teams understand the impact of their work – including how much attention their research and independent medical education activities receive and the sentiment regarding those activities. That understanding feeds directly into publication strategy.

Sunmedia serves around 2,000 corporate customers across various sectors, with pharmaceutical as its core market, including most major pharma companies in Japan.

Koji Yamashita , CEO, Sunmedia, said: "Medical affairs teams in Japan have long needed a clearer way to demonstrate the value of their work to leadership. Combining Dimensions and Altmetric data with a narrative-driven approach gives us a way to help them tell that story with real evidence behind it, in a market where this kind of reporting hasn't really existed before."

Gareth Williams , Director of Partnerships, Digital Science, said: "We're excited to partner with Sunmedia to bring new insight to medical affairs teams in Japan. This partnership provides medical affairs teams with clear insights into how their research output is received, enabling them to internally justify and externally measure their impact in clear, accessible terms."

About Sunmedia

Established in 1964, Sunmedia Co., Ltd. is Japan’s leading innovation-driven content solutions and market development partner, connecting global scholarly publishers, AI companies, and research solution providers with the Japanese scientific community. For over 60 years, Sunmedia has provided top-tier research content solution tools, e-journal hosting, rights permissions, and single-article sales to university libraries, hospitals, corporations, and government agencies across Japan. Headquartered in Tokyo, the company accelerates business growth and supports academic advancement through deep local market knowledge and trusted strategic partnerships.

For more information, please visit: https://www.sunmedia.co.jp

About Digital Science

Digital Science is an AI-focused technology company providing innovative solutions to complex challenges faced by researchers, universities, governments, funders, industry, and publishers. We work in partnership to advance global research for the benefit of society. Through our brands – Altmetric, Dimensions, Figshare, IFI CLAIMS Patent Services, metaphacts, Overleaf, ReadCube, Symplectic, and Writefull – we believe when we solve problems together, we drive progress for all. Visit digital-science.com and follow Digital Science on Bluesky , on X or on LinkedIn .

Media contacts
Sunmedia: e-port@sunmedia.co.jp

Digital Science: David Ellis , Manager, Media & PR: d.ellis@digital-science.com

SOURCE: Digital Science

AM Best Affirms Credit Ratings of China Taiping Insurance (Singapore) Pte. Ltd.

SINGAPORE, Oct 19 (Bernama-BUSINESS WIRE) -- AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a” (Excellent) of China Taiping Insurance (Singapore) Pte. Ltd. (CTPIS) (Singapore). The outlook of these Credit Ratings (ratings) is stable. CTPIS is a wholly owned subsidiary of China Taiping Insurance Holdings Company Limited, which is ultimately majority owned by China Taiping Insurance Group Ltd. (TPG), a China state-owned financial and insurance group.

The ratings reflect CTPIS’ balance sheet strength, which AM Best assesses as strong, as well as its adequate operating performance, neutral business profile and appropriate enterprise risk management (ERM). In addition, CTPIS benefits from rating enhancement as a member of the TPG group.

CTPIS’ balance sheet strength is underpinned by risk-adjusted capitalisation, which is expected to remain at the strongest level over the intermediate term, as measured by Best’s Capital Adequacy Ratio (BCAR). Additionally, CTPIS benefits from strong financial flexibility as demonstrated by capital injections provided by the TPG group in recent years to support the development of its life insurance operations. The company’s investment portfolio consists of cash, deposits and fixed-income securities, albeit with some exposure to higher-risk asset classes such as equities. CTPIS has a moderate reinsurance usage to support the underwriting of large limit risks and life insurance products; however, the credit risk is partially mitigated by the company’s utilisation of a well-rated reinsurance panel.

CTPIS’ operating performance is assessed as adequate, with a return-on-equity ratio of 6% in 2025 (2024: 5.8%). The 2025 operating income was mainly supported by profitable non-life business, while the life business showed improvement during the year. Operating performance remained profitable in the first half of 2026. CTPIS’ investment income is comprised mainly of interest and dividend income and continues to support overall profitability.

AM Best assesses CTPIS’ business profile as neutral. The company is a medium-size composite insurer, domiciled in Singapore, with a long-established position within that country’s non-life segment and an increasing position in the life segment. CTPIS maintains a well-diversified underwriting portfolio, with life insurance operations contributing approximately half of gross premiums written in 2025, albeit the portfolio is geographically concentrated in Singapore. The company benefits from its affiliation with the TPG group, which provides it a level of preferential access to insured risks associated with China-based enterprises in the Singapore market.

The rating enhancement reflects both the implicit and explicit support CTPIS receives from the TPG group. While CTPIS’ operations account for a small portion of the group’s consolidated revenue and earnings, it is considered strategically important to the group in terms of accessing the Singapore insurance market and growing its overseas business.

Ratings are communicated to rated entities prior to publication. Unless stated otherwise, the ratings were not amended subsequent to that communication.

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings. For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments.

AM Best is a global credit rating agency, news publisher and data analytics provider specialising in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2026 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

View source version on businesswire.com:
https://www.businesswire.com/news/home/20261016696180/en/

Contact

Sin Yee Chuah, CFA
Senior Financial Analyst
+65 6303 5022
sinyee.chuah@ambest.com

Victoria Ohorodnyk
Senior Director, Analytics
+65 6303 5020
victoria.ohorodnyk@ambest.com

Christopher Sharkey
Associate Director, Public Relations
+1 908 882 2310
christopher.sharkey@ambest.com

Al Slavin
Senior Public Relations Specialist
+1 908 882 2318
al.slavin@ambest.com

Source : AM Best

MONGOLIAN MINING’S Q3 COKING COAL SALES FALL 26 PCT

KUALA LUMPUR, Oct 16 (Bernama) -- Mongolian Mining Corporation’s washed coking coal sales fell 26 per cent quarter-on-quarter to about 1,996.9 kilotonnes (kt) in the third quarter (Q3) ended Sept 30, even as coking coal prices in China rebounded strongly on tighter domestic supply.


Sales were also down 13 per cent from 2,303.2 kt a year earlier, according to the company’s unaudited operational update.


The number of coal trucks crossing the Ganqimaodu border point into China fell to an average of 897 per operating day during the quarter. This was 34 per cent and 29 per cent lower than the averages of 1,366 and 1,270 trucks in the second and first quarters, respectively.


However, the year-to-date average of 1,177 trucks per operating day was 15 per cent higher than the 2025 full-year average of 1,023, the company said in a statement.


Combined output from its Ukhaa Khudag and Baruun Naran mines showed raw coal mined rising eight per cent quarter-on-quarter and 33 per cent year-on-year to 4,791.2 kt.


Coking coal processed fell six per cent from the previous quarter to 4,253.2 kt but rose 13 per cent year-on-year, while washed coking coal production dropped 11 per cent quarter-on-quarter to 2,503.1 kt, up 19 per cent from a year earlier.


At its Bayan Khundii gold mine, ore mined rose 68 per cent quarter-on-quarter to 414.9 kt, ore processed increased seven per cent to 164.5 kt and gold sales edged up one per cent to 11,853 ounces (oz).


The company’s average realised gold price fell four per cent quarter-on-quarter to US$4,315 an ounce, but was 13 per cent higher than US$3,805 a year earlier. (US$1 = RM4.08)


Mongolian Mining Corporation sells its coking coal through auctions on the Mongolian Stock Exchange.


-- BERNAMA

BIOLAB HOLDINGS REBRANDS AS EMERANOVA, EYES GLOBAL EXPANSION

EmeraNova seeks partners around the world to bring promising technologies to market quickly and equip clinicians with advanced, effective solutions.

KUALA LUMPUR, Oct 16 (Bernama) -- BioLab Holdings has rebranded as EmeraNova, as it widens its focus from chronic wound care to tissue restoration across medical specialities, healing phases and care settings.

The company said the new corporate identity reflects its plan to build a global platform that identifies promising technologies and speeds up their path into clinical practice. The name combines emerging (Emer) and new (Nova), reflecting its aim to pursue new technologies.

“BioLab was built on a commitment to improve patients’ lives. With EmeraNova, we are widening that lens,” said EmeraNova President and Chief Executive Officer, Jaime Leija in a statement.

He said the company was looking at technologies around the world to create a more connected ecosystem of care and bring the right innovations to clinicians and patients faster.

EmeraNova said it aims to expand into new care settings, including acute care and hospital outpatient departments (HOPDs), while continuing to serve outpatient and mobile wound clinics and to supply its existing amniotic membrane products.

It also hopes to broaden its clinical applications into surgery, sports medicine, vascular care and aesthetics, and to take its products overseas through international commercialisation partnerships.

EmeraNova organises its products into eight areas, namely Assess & Differentiate, Diagnose, Debride, Control, Prepare, Restore & Regenerate, Reassess, and Remodel Tissue. Across these categories, it is seeking partners worldwide to bring promising technologies to market quickly.

The company said its clinical research covers multiple products, with four clinical trials and three published, peer-reviewed retrospective studies run in 2026.

EmeraNova will present its new brand at the Symposium on Advanced Wound Care (SAWC) in Las Vegas from Oct 16 to 18.

-- BERNAMA